280 related articles for article (PubMed ID: 29393500)
1. Indoleamine 2, 3-dioxygenase regulation of immune response (Review).
Wu H; Gong J; Liu Y
Mol Med Rep; 2018 Apr; 17(4):4867-4873. PubMed ID: 29393500
[TBL] [Abstract][Full Text] [Related]
2. The role of indoleamine 2,3-dioxygenase in allergic disorders.
Esmaeili SA; Hajavi J
Mol Biol Rep; 2022 Apr; 49(4):3297-3306. PubMed ID: 35028850
[TBL] [Abstract][Full Text] [Related]
3. Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease.
Macchiarulo A; Camaioni E; Nuti R; Pellicciari R
Amino Acids; 2009 Jul; 37(2):219-29. PubMed ID: 18612775
[TBL] [Abstract][Full Text] [Related]
4. Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality.
Jasperson LK; Bucher C; Panoskaltsis-Mortari A; Mellor AL; Munn DH; Blazar BR
Blood; 2009 Dec; 114(24):5062-70. PubMed ID: 19828695
[TBL] [Abstract][Full Text] [Related]
5. Expression and regulation of immune-modulatory enzyme indoleamine 2,3-dioxygenase (IDO) by human airway epithelial cells and its effect on T cell activation.
Aldajani WA; Salazar F; Sewell HF; Knox A; Ghaemmaghami AM
Oncotarget; 2016 Sep; 7(36):57606-57617. PubMed ID: 27613847
[TBL] [Abstract][Full Text] [Related]
6. Role of indoleamine 2,3-dioxygenase in acute myeloid leukemia.
Sobash PT; Kolhe R; Karim NA; Guddati AK; Jillella A; Kota V
Future Oncol; 2020 Dec; 16(36):3085-3094. PubMed ID: 32976029
[TBL] [Abstract][Full Text] [Related]
7. Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells.
Curti A; Trabanelli S; Onofri C; Aluigi M; Salvestrini V; Ocadlikova D; Evangelisti C; Rutella S; De Cristofaro R; Ottaviani E; Baccarani M; Lemoli RM
Haematologica; 2010 Dec; 95(12):2022-30. PubMed ID: 20801903
[TBL] [Abstract][Full Text] [Related]
8. Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance.
Johnson TS; Munn DH
Immunol Invest; 2012; 41(6-7):765-97. PubMed ID: 23017145
[TBL] [Abstract][Full Text] [Related]
9. Computational study on new natural compound inhibitors of indoleamine 2,3-dioxygenase 1.
Jiang S; Li H; Piao L; Jin Z; Liu J; Chen S; Liu LL; Shao Y; Zhong S; Wu B; Li W; Ren J; Zhang Y; Wang H; Jin R
Aging (Albany NY); 2020 Jun; 12(12):11349-11363. PubMed ID: 32568737
[TBL] [Abstract][Full Text] [Related]
10. Targeting indoleamine 2,3-dioxygenase (IDO) to counteract tumour-induced immune dysfunction: from biochemistry to clinical development.
Rutella S; Bonanno G; De Cristofaro R
Endocr Metab Immune Disord Drug Targets; 2009 Jun; 9(2):151-77. PubMed ID: 19519465
[TBL] [Abstract][Full Text] [Related]
11. Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences.
Davar D; Bahary N
Target Oncol; 2018 Apr; 13(2):125-140. PubMed ID: 29302770
[TBL] [Abstract][Full Text] [Related]
12. Research progress of indoleamine 2,3-dioxygenase inhibitors.
Jiang T; Sun Y; Yin Z; Feng S; Sun L; Li Z
Future Med Chem; 2015; 7(2):185-201. PubMed ID: 25686005
[TBL] [Abstract][Full Text] [Related]
13. Indoleamine 2,3-dioxygenase and dendritic cell tolerogenicity.
Harden JL; Egilmez NK
Immunol Invest; 2012; 41(6-7):738-64. PubMed ID: 23017144
[TBL] [Abstract][Full Text] [Related]
14. Uveal melanoma expression of indoleamine 2,3-deoxygenase: establishment of an immune privileged environment by tryptophan depletion.
Chen PW; Mellon JK; Mayhew E; Wang S; He YG; Hogan N; Niederkorn JY
Exp Eye Res; 2007 Nov; 85(5):617-25. PubMed ID: 17870068
[TBL] [Abstract][Full Text] [Related]
15. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape.
Katz JB; Muller AJ; Prendergast GC
Immunol Rev; 2008 Apr; 222():206-21. PubMed ID: 18364004
[TBL] [Abstract][Full Text] [Related]
16. Influence of tryptophan contained in 1-Methyl-Tryptophan on antimicrobial and immunoregulatory functions of indoleamine 2,3-dioxygenase.
Schmidt SK; Siepmann S; Kuhlmann K; Meyer HE; Metzger S; Pudelko S; Leineweber M; Däubener W
PLoS One; 2012; 7(9):e44797. PubMed ID: 23028625
[TBL] [Abstract][Full Text] [Related]
17. Molecular docking and dynamic simulation studies evidenced plausible immunotherapeutic anticancer property by Withaferin A targeting indoleamine 2,3-dioxygenase.
Reddy SV; Reddy KT; Kumari VV; Basha SH
J Biomol Struct Dyn; 2015; 33(12):2695-709. PubMed ID: 25671592
[TBL] [Abstract][Full Text] [Related]
18. Indoleamine 2,3-dioxygenase depletes tryptophan, activates general control non-derepressible 2 kinase and down-regulates key enzymes involved in fatty acid synthesis in primary human CD4+ T cells.
Eleftheriadis T; Pissas G; Antoniadi G; Liakopoulos V; Stefanidis I
Immunology; 2015 Oct; 146(2):292-300. PubMed ID: 26147366
[TBL] [Abstract][Full Text] [Related]
19. Indoleamine 2,3-dioxygenase in transplantation.
Mulley WR; Nikolic-Paterson DJ
Nephrology (Carlton); 2008 Jun; 13(3):204-11. PubMed ID: 18221253
[TBL] [Abstract][Full Text] [Related]
20. Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies.
Selvan SR; Dowling JP; Kelly WK; Lin J
Curr Cancer Drug Targets; 2016; 16(9):755-764. PubMed ID: 26517538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
